Cytokinetics Inc
NASDAQ:CYTK
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
44.6
108.06
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Cytokinetics Inc
Cash from Financing Activities
Cytokinetics Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Cytokinetics Inc
NASDAQ:CYTK
|
Cash from Financing Activities
$1.1B
|
CAGR 3-Years
56%
|
CAGR 5-Years
97%
|
CAGR 10-Years
38%
|
||
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$2.8B
|
CAGR 3-Years
45%
|
CAGR 5-Years
25%
|
CAGR 10-Years
1%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$6.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
||
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
-$5.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$1.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.5B
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Cytokinetics Inc
Glance View
Cytokinetics Inc., rooted firmly in the heart of California's biotechnology hub, has carved a niche in the complex arena of muscle biology. Founded in 1998, the company has focused its considerable expertise on the intricacies of muscle function, especially targeting conditions characterized by impaired muscle performance such as heart failure, ALS, and even SMA. Rather than pursuing the well-trodden paths of traditional pharmaceuticals, Cytokinetics delves into the uncharted realms of muscle contractility, leveraging its proprietary muscle biology expertise to develop small molecule therapeutics. Their pipeline is rich with candidates that promise to enhance muscle function, representing a blend of hope and scientific innovation for conditions that, until now, have seen few breakthroughs. As a business, Cytokinetics operates at the confluence of innovative science and strategic partnerships. Financially, the company nurtures its pipeline through the judicious blend of equity financing, collaboration revenues, and milestone payments. Strategic alliances with larger pharmaceutical companies, such as collaborations previously established with Amgen and Astellas, play a pivotal role; these partnerships not only provide capital but also benefit from shared resources and expanded market reach. With therapies still largely in development, the company's revenue streams are intertwined with the success of clinical trials and approvals, rendering each scientific step a potential catalyst for investor interest and market value growth.
See Also
What is Cytokinetics Inc's Cash from Financing Activities?
Cash from Financing Activities
1.1B
USD
Based on the financial report for Sep 30, 2024, Cytokinetics Inc's Cash from Financing Activities amounts to 1.1B USD.
What is Cytokinetics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
38%
Over the last year, the Cash from Financing Activities growth was 1 293%. The average annual Cash from Financing Activities growth rates for Cytokinetics Inc have been 56% over the past three years , 97% over the past five years , and 38% over the past ten years .